METTL3 and cancer: Indeed, recently, inhibition of METTL3 with STM4257 and another METTL3 inhibitor (STM3006) was shown to stimulate an interferon response, augment antigen-dependent killing of cancer cells by T-cells in vitro and exhibit far greater in vivo pre-clinical activity when in combination with anti-PD1 therapy34.